Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
How precise cancer care is
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

A phase 1 trial of Rivogenlecleucel run by Fred Hutchinson Cancer Center, withdrawn before enrolling.

Withdrawn

Overview Connected10

Overview

Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant is a phase 1 interventional study registered as NCT03807063 by Fred Hutchinson Cancer Center, started 2020-01-02. Conditions recorded: Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloproliferative Neoplasm, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Chronic Myelomonocytic Leukemia and Recurrent Myelodysplastic Syndrome. Interventions recorded: Rivogenlecleucel and Rimiducid.

Setting

Phase I Trial With "Off-The-Shelf" Third-Party BPX-501 Donor Lymphocyte Immunotherapy to Treat Persistence or Relapse of Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Phase

Phase 1

Sponsor

Fred Hutchinson Cancer Center

Registry

Enrolled

Connected

10

Similar pages

Trial
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia and the tag pipeline.
Trial
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia and the tag pipeline.
Trial
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Trial
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia and the tag pipeline.
Trial
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia and the tag pipeline.
Trial
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Shares Chronic myeloid leukaemia (CML), Myelodysplastic syndromes / neoplasms (MDS), Chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia and the tag pipeline.
Trial
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Trial
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.

cancers

Acute lymphoblastic leukaemia Acute myeloid leukaemia Blastic plasmacytoid dendritic cell neoplasm (BPDCN)Chronic lymphocytic leukaemia Chronic myeloid leukaemia (CML)Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms Myelodysplastic syndromes / neoplasms (MDS)Myeloproliferative neoplasms (PV, ET, myelofibrosis)

drugs

Phase 3Allogeneic polyclonal T cell therapy with an inducible caspase-9 safety switch

Rivogenlecleucel

companies

Bellicum Pharmaceuticals

Evidence strength0/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1+4
No structured primary endpoint0
Result: withdrawn-20
No independent replication recorded0

Formula disclosed on the evidence page.

Make correction

Report a readout

Connected

cancers8
drugs1
companies1

Sources

Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.

ClinicalTrials.gov · 1

ClinicalTrials.gov NCT03807063

A source that has moved or gone is reported by the weekly link check. /audit/

Sourced, not expert-reviewed

Machine-readable versions of Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct03807063/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct03807063.

WebMCP tools registered on this page: onco_search, onco_get_entity.